Development of a novel tricyclic class of potent and selective FIXa inhibitors.
Meng, D., Andre, P., Bateman, T.J., Berger, R., Chen, Y.H., Desai, K., Dewnani, S., Ellsworth, K., Feng, D., Geissler, W.M., Guo, L., Hruza, A., Jian, T., Li, H., Metzger, J., Parker, D.L., Reichert, P., Sherer, E.C., Smith, C.J., Sonatore, L.M., Tschirret-Guth, R., Wu, J., Xu, J., Zhang, T., Campeau, L.C., Orr, R., Poirier, M., McCabe-Dunn, J., Araki, K., Nishimura, T., Sakurada, I., Hirabayashi, T., Wood, H.B.(2015) Bioorg Med Chem Lett 25: 5437-5443
- PubMed: 26318999 
- DOI: https://doi.org/10.1016/j.bmcl.2015.07.078
- Primary Citation of Related Structures:  
5EGM - PubMed Abstract: 
Using structure based drug design, a novel class of potent coagulation factor IXa (FIXa) inhibitors was designed and synthesized. High selectivity over FXa inhibition was achieved. Selected compounds were evaluated in rat IV/PO pharmacokinetic (PK) studies and demonstrated desirable oral PK profiles ...